In support of this hypothesis, Yu et al observed no effects of metformin (850 mg twice/day) treatment on insulin-stimulated peripheral glucose metabolism in T2D patients rendered normoglycemic following 4 weeks of continuous subcutaneous insulin (74). This evidence concerns the gene INS and type 2 diabetes mellitus.